Both in Biotechnology
Beam Therapeutics vs Recursion Pharmaceuticals
Over the past year BEAM returned +12.3% and RXRX returned −25.9%; their daily moves had a correlation of 0.59.
BEAM +12.3% RXRX −25.9%Growth of $1, one year, split-adjusted
| Metric | BEAM | RXRX |
|---|---|---|
| Price | $27.23 | $4.03 |
| Market cap | $2.81B | $2.41B |
| Today | −5.58% | −4.95% |
| 1 month | +11.6% | −1.0% |
| 6 months | −11.3% | +18.9% |
| Year to date | −1.8% | −1.5% |
| 1 year | +9.9% | −31.3% |
| Revenue growth (YoY) | −94.2% | −60.1% |
| Gross margin | 100.0% | −49.8% |
| Net margin | −25036.3% | −1708.0% |
| P/E (TTM) | — | — |
| Price / sales | 18.0× | 43.9× |
| Net cash | $1.05B | $531.5M |
| Dividend yield | — | — |
| Volatility (60d) | 62.4% | 94.5% |
| Short % of float | 32.0% | 37.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).